BridgeBio Pharma (BBIO) PT Lowered to $55 at JPMorgan
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $74.47 -1.25%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Join SI Premium – FREE
JPMorgan analyst Anupam Rama lowered the price target on BridgeBio Pharma (NASDAQ: BBIO) to $55.00 (from $58.00) while maintaining a Overweight rating.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
- Brown Forman (BF-B) PT Raised to $30 at UBS Following Q1 Results
- BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
